Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT01714089 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: RNS60 125 ml
DRUG: RNS60 250 ml
DRUG: Interferon beta 1a

Sponsor

Revalesio Corporation